Azura Ophthalmics announced it has received positive feedback from a pre-New Drug Application (NDA) meeting with the US Food ...

TEL AVIV, Israel--(BUSINESS WIRE)--Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today ...

Please provide your email address to receive an email when new articles are posted on . LipiFlow has consistently demonstrated safety and efficacy in treating meibomian gland dysfunction. The review ...

Meibomian gland dysfunction (MGD) is underdiagnosed and undertreated, with asymptomatic disease far more common than symptomatic disease. As the condition progresses, patients who were initially ...

A systematic review found that there were currently a limited number of clinical trials evaluating treatment for dry eye disease (DED) that is associated with meibomian gland dysfunction (MGD). Future ...

Please provide your email address to receive an email when new articles are posted on . Eyes that received LipiFlow treatment before cataract surgery had improved meibomian gland scores compared with ...

Dry eye disease (DED) is one of the most common ocular surface disorders. All DED involves an imbalance between tear production and evaporation. Most cases of DED are driven by excessive evaporation, ...